Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization

Objective To investigative whether the odds tumor enhancement ratio (OTER) on cross-sectional imaging is a prognostic factor for hepatocellular carcinoma after transarterial chemoembolization (TACE). Methods This study involved 126 patients who underwent TACE from May 2015 to March 2019. The signal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xi-Yuan Yang, Jiang-Bei Deng, Tian-Zhi An, Shi Zhou, Jun-Xiang Li
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9e7207538f2746039881f8a97ea5d805
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e7207538f2746039881f8a97ea5d805
record_format	dspace
spelling	oai:doaj.org-article:9e7207538f2746039881f8a97ea5d8052021-12-02T03:04:09ZTumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization1473-230010.1177/03000605211058367https://doaj.org/article/9e7207538f2746039881f8a97ea5d8052021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211058367https://doaj.org/toc/1473-2300Objective To investigative whether the odds tumor enhancement ratio (OTER) on cross-sectional imaging is a prognostic factor for hepatocellular carcinoma after transarterial chemoembolization (TACE). Methods This study involved 126 patients who underwent TACE from May 2015 to March 2019. The signal intensity/Hounsfield units (HU) was measured by placing regions of interest on the tumor and surrounding liver in unenhanced and arterial-phase contrast-enhanced cross-sectional images. The OTER was calculated as follows: OTER = (HU TUMORart − HU TUMORun )/ (HU LIVERart − HU LIVERun ). Univariate analysis was performed to determine the factors associated with overall survival (OS). Variables with a P value of <0.10 were included in the multivariate Cox regression analysis. Results The median OS was 757 days. Tumors with a peripheral location, small size, and low OTER had better OS than those with a central location, large size, and high OTER. OS did not differ according to the extent of tumor involvement or tumor enhancement pattern. The OTER, tumor location, and size were included in the multivariate Cox regression analysis. A low OTER was the predictor of better OS. Conclusion A high OTER is a risk factor for poor OS in patients undergoing TACE. This should be taken into consideration before the procedure.Xi-Yuan YangJiang-Bei DengTian-Zhi AnShi ZhouJun-Xiang LiSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Xi-Yuan Yang Jiang-Bei Deng Tian-Zhi An Shi Zhou Jun-Xiang Li Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
description	Objective To investigative whether the odds tumor enhancement ratio (OTER) on cross-sectional imaging is a prognostic factor for hepatocellular carcinoma after transarterial chemoembolization (TACE). Methods This study involved 126 patients who underwent TACE from May 2015 to March 2019. The signal intensity/Hounsfield units (HU) was measured by placing regions of interest on the tumor and surrounding liver in unenhanced and arterial-phase contrast-enhanced cross-sectional images. The OTER was calculated as follows: OTER = (HU TUMORart − HU TUMORun )/ (HU LIVERart − HU LIVERun ). Univariate analysis was performed to determine the factors associated with overall survival (OS). Variables with a P value of <0.10 were included in the multivariate Cox regression analysis. Results The median OS was 757 days. Tumors with a peripheral location, small size, and low OTER had better OS than those with a central location, large size, and high OTER. OS did not differ according to the extent of tumor involvement or tumor enhancement pattern. The OTER, tumor location, and size were included in the multivariate Cox regression analysis. A low OTER was the predictor of better OS. Conclusion A high OTER is a risk factor for poor OS in patients undergoing TACE. This should be taken into consideration before the procedure.
format	article
author	Xi-Yuan Yang Jiang-Bei Deng Tian-Zhi An Shi Zhou Jun-Xiang Li
author_facet	Xi-Yuan Yang Jiang-Bei Deng Tian-Zhi An Shi Zhou Jun-Xiang Li
author_sort	Xi-Yuan Yang
title	Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
title_short	Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
title_full	Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
title_fullStr	Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
title_full_unstemmed	Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
title_sort	tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/9e7207538f2746039881f8a97ea5d805
work_keys_str_mv	AT xiyuanyang tumorenhancementratiowithunenhancedimagingisanindependentprognosticfactorforpatientswithhepatocellularcarcinomaaftertransarterialchemoembolization AT jiangbeideng tumorenhancementratiowithunenhancedimagingisanindependentprognosticfactorforpatientswithhepatocellularcarcinomaaftertransarterialchemoembolization AT tianzhian tumorenhancementratiowithunenhancedimagingisanindependentprognosticfactorforpatientswithhepatocellularcarcinomaaftertransarterialchemoembolization AT shizhou tumorenhancementratiowithunenhancedimagingisanindependentprognosticfactorforpatientswithhepatocellularcarcinomaaftertransarterialchemoembolization AT junxiangli tumorenhancementratiowithunenhancedimagingisanindependentprognosticfactorforpatientswithhepatocellularcarcinomaaftertransarterialchemoembolization
_version_	1718401998624129024

Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization

Ejemplares similares